GlassScriptPhysician profile
Casey J Cronan
NPI 1821415647
$1,785.25
in general payments reported to CMS, 2019-2025
14 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $262 · 2021: $131 · 2022: $184 · 2023: $129 · 2024: $177 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $633.51 | 2019-2025 | Dovato, Cabenuva |
| Gilead Sciences, INC. | $343.59 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $176.98 | 2019-2022 | |
| Abbvie INC. | $118.95 | 2019-2025 | |
| Insmed, INC. | $118.66 | 2019-2023 | Arikayce |
| Janssen Biotech, INC. | $85.54 | 2019-2020 | |
| Theratechnologies INC. | $63.20 | 2019 | |
| Paratek Pharmaceuticals, INC. | $63.12 | 2020 | |
| Pfizer INC. | $48.67 | 2019-2025 | |
| Angiodynamics, INC. | $42.15 | 2024 | Angiovac |
| Melinta Therapeutics, LLC | $35.61 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Astellas Pharma US INC | $22.72 | 2023 | Cresemba |
| Tetraphase Pharmaceuticals, INC. | $17.08 | 2019 | |
| Janssen Scientific Affairs, LLC | $15.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Cronan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.